Trial · NCT03737994
Results by group51
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 51
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria | Lorlatinib | Mutation = I1171: BOR of CR or PR | 1 | Participants | |
| Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria | LDK378 (Ceritinib) | Mutation = I1171: BOR of CR or PR | 0 | Participants | |
| Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria | Brigatinib | Mutation = I1171: BOR of CR or PR | 0 | Participants | |
| Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria | Lorlatinib | Mutation = None: BOR of CR or PR | 2 | Participants | |
| Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria | Brigatinib | Mutation = None: BOR of CR or PR | 1 | Participants | |
| Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria | Ensartinib | Mutation = None: BOR of CR or PR | 0 | Participants | |
| Progression-free Survival (PFS), Per Investigator Assessment Using RECIST v1.1 Criteria | Lorlatinib | Mutation = I1107: progression or death | 0 | Participants | |
| Progression-free Survival (PFS), Per Investigator Assessment Using RECIST v1.1 Criteria | LDK378 (Ceritinib) | Mutation = I1107: progression or death | 0 | Participants | |
| Progression-free Survival (PFS), Per Investigator Assessment Using RECIST v1.1 Criteria | Brigatinib | Mutation = I1107: progression or death | 1 | Participants | |
| Progression-free Survival (PFS), Per Investigator Assessment Using RECIST v1.1 Criteria | Lorlatinib | Mutation = none: progression or death | 1 | Participants | |
| Progression-free Survival (PFS), Per Investigator Assessment Using RECIST v1.1 Criteria | Brigatinib | Mutation = none: progression or death | 1 | Participants | |
| Progression-free Survival (PFS), Per Investigator Assessment Using RECIST v1.1 Criteria | Ensartinib | Mutation = none: progression or death | 2 | Participants | |
| Duration of Overall Response, Per Investigator Assessment Using RECIST v1.1 | Lorlatinib | Mutation = I1171 | 27.9 | Full Range 27.9 to 27.9 | months |
| Duration of Overall Response, Per Investigator Assessment Using RECIST v1.1 | Lorlatinib | Mutation = None | 19.2 | Full Range 9.4 to 29.1 | months |
| Duration of Overall Response, Per Investigator Assessment Using RECIST v1.1 | Brigatinib | Mutation = None | 3.5 | Full Range 3.5 to 3.5 | months |
| Overall Survival (OS) | Lorlatinib | Mutation = I1171: deaths | 0 | Participants | |
| Overall Survival (OS) | LDK378 (Ceritinib) | Mutation = I1171: deaths | 0 | Participants | |
| Overall Survival (OS) | Brigatinib | Mutation = I1171: deaths | 0 | Participants | |
| Overall Survival (OS) | Lorlatinib | Mutation = None: deaths | 0 | Participants | |
| Overall Survival (OS) | Brigatinib | Mutation = None: deaths | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03737994/results